O slideshow foi denunciado.

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

0

Compartilhar

1 de 22
1 de 22

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

0

Compartilhar

Baixar para ler offline

DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from report are:

As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.

DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from report are:

As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.

Mais Conteúdo rRelacionado

Semelhante a Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

  1. 1. Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies LAS VEGAS, April 28, 2020 -- The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others. DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio. Key Highlights from report are:  As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017– 2030.  There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.  The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.
  2. 2.  One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments. Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM. The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.
  3. 3. Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more. Drugs covered in the report are:- There are several key players robustly involved in developing potential products such as  Nazartinib (EGF816)  Capmatinib (INC280)  Tepmetko (tepotinib)  Merestinib  JNJ-61186372 (JNJ-6372)  Vemurafenib Plus Cobimetinib  X-396 (Ensartinib)  Tedopi (OSE2101)  Selpercatinib (LY3527723/ LOXO-292)  SAR408701  Braftovi (encorafinib) + Mektovi (binimetinib)  PADCEV (enfortumab vedotin/ASG-22ME)  Pralsetinib (BLU-667)  TAK-788: Canakinumab (ACZ885)  Avelumab (Bavencio)  Veliparib (ABT-888): Sitravatinib (MGCD516)  Tesevatinib  Romiplostim: Cabozantinib  Sym015  AMG 510  INCMGA00012 (MGA012)
  4. 4.  Libtayo (Cemiplimab)  Bavituximab  M7824 (Bintrafusp alfa)  And many others Key Players covered in the report are:-  Novartis Pharmaceuticals  Merck KGaA  Eli Lilly and Company  Janssen Research & Development  Hoffmann-La Roche  Xcovery  BeyondSpring Pharmaceuticals  OSE Immunotherapeutics  Sanofi  Pfizer  Astellas Pharma  Seattle Genetics  Blueprint Medicines Corporation  Takeda  AbbVie  Kadmon Corporation  Amgen  Symphogen  Regeneron Pharmaceuticals  Peregrine Pharmaceuticals  Avid Bioservices  GlaxoSmithKline And many others The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well. Market Driver
  5. 5. Market Barrier The reasons for buying this report:  The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.  Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.  Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.  Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.  Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.
  6. 6.  Reimbursement scenario and Key Opinion Leader Views Table of Contents 1. Key Insights 2. Executive Summary of NSCLC 3. SWOT Analysis of NSCLC 4. NSCLC: Market Overview at a Glance 4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country 4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country 4.3. Total Market Share (%) Distribution of NSCLC in 2017: By Mutations/ biomarkers 4.4. Total Market Share (%) Distribution of NSCLC in 2030: By Mutations/ biomarkers 4.5. NSCLC Revenue Summary by Mutations/ biomarkers 5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview 5.1. Introduction 5.1.1. Cellular Classification of NSCLC 5.1.2. Signs and Symptoms of NSCLC 5.1.3. Risk Factors of Lung Cancer 5.1.4. Causes of NSCLC 5.1.5. Disease Biology: NSCLC 6. Diagnosis of NSCLC 6.1. Diagnostic Algorithm for NSCLC
  7. 7. 6.2. Stages of NSCLC 6.3. Staging System 7. Epidemiology and Patient Population 7.1. Epidemiology Key Findings 7.2. Assumptions and Rationale: 7MM 7.3. Epidemiology Scenario: 7MM 7.3.1. Total Incident cases of NSCLC patients in the 7MM 7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM 7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM 7.4. The United States Epidemiology 7.4.1. Total Incident cases of NSCLC patients in the United States 7.4.2. Total Incident cases of NSCLC patients by Histology in the United States 7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States 7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States 8. EU-5 Epidemiology 8.1. Germany 8.1.1. Total Incident cases of NSCLC patients in Germany 8.1.2. Total Incident cases of NSCLC patients by Histology in Germany 8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany 8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany 8.2. France
  8. 8. 8.2.1. Total Incident cases of NSCLC patients in France 8.2.2. Total Incident cases of NSCLC patients by Histology in France 8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France 8.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France 8.3. Italy 8.3.1. Total Incident cases of NSCLC patients in Italy 8.3.2. Total Incident cases of NSCLC patients by Histology in Italy 8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy 8.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy 8.4. Spain 8.4.1. Total Incident cases of NSCLC patients in Spain 8.4.2. Total Incident cases of NSCLC patients by Histology in Spain 8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain 8.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain 8.5. The United Kingdom 8.5.1. Total Incident cases of NSCLC patients in the United Kingdom 8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom 8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom 8.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom 9. Japan Epidemiology 9.1. Japan
  9. 9. 9.1.1. Total Incident cases of NSCLC patients in Japan 9.1.2. Total Incident cases of NSCLC patients by Histology in Japan 9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan 9.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan 10. Current Treatment Practices: NSCLC 10.1. Advanced/Metastatic NSCLC Treatment Algorithm 10.2. Chemotherapy 10.3. Targeted Therapy 10.4. Immunotherapy 10.5. Surgery 10.6. Radiation Therapy 10.7. Stage-wise Treatment Options of NSCLC 11. Guideline of NSCLC 11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020 11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up 11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018 11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018 12. Unmet Needs of NSCLC 13. Key Endpoints in NSCLC Clinical Trials 14. Marketed Therapies 14.1. Key Cross
  10. 10. 14.2. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech) 14.2.1. Product Description 14.2.2. Regulatory Milestones 14.2.3. Other Developmental Activities 14.2.4. Pivotal Clinical Trials 14.2.5. Ongoing Current Pipeline Activity 14.3. Imfinzi (Durvalumab): AstraZeneca 14.3.1. Product Description 14.3.2. Regulatory Milestones 14.3.3. Other Developmental Activities 14.3.4. Pivotal Clinical Trials 14.3.5. Ongoing Current Pipeline Activity 14.3.6. Safety and Efficacy of Ongoing Clinical Trials 14.4. Opdivo (Nivolumab): Bristol-Myers Squibb 14.4.1. Product Description 14.4.2. Regulatory Milestones 14.4.3. Other Developmental Activities 14.4.4. Pivotal Clinical Trials 14.4.5. Ongoing Current Pipeline Activity 14.5. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche 14.5.1. Product Description 14.5.2. Regulatory Milestones
  11. 11. 14.5.3. Other Developmental Activities 14.5.4. Pivotal Clinical Trials 14.5.5. Ongoing Current Pipeline Activity 14.6. Keytruda (Pembrolizumab): Merck 14.6.1. Product Description 14.6.2. Regulatory Milestones 14.6.3. Other Developmental Activities 14.6.4. Pivotal Clinical Trials 14.6.5. Ongoing Current Pipeline Activity 14.7. Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis 14.7.1. Product Description 14.7.2. Regulatory Milestones 14.7.3. Other Developmental Activities 14.7.4. Pivotal Clinical Trials 14.8. Tagrisso(Osimertinib): AstraZeneca 14.8.1. Product Description 14.8.2. Regulatory Milestones 14.8.3. Other Developmental Activities 14.8.4. Pivotal Clinical Trials 14.8.5. Ongoing Current Pipeline Activity 14.9. Lorbrena/Lorviqua (Lorlatinib): Pfizer 14.9.1. Product Description
  12. 12. 14.9.2. Regulatory Milestones 14.9.3. Other Developmental Activities 14.9.4. Pivotal Clinical Trials 14.9.5. Ongoing Current Pipeline Activity 14.10. Vizimpro(Dacomitinib): Pfizer 14.10.1. Product Description 14.10.2. Regulatory Milestones 14.10.3. Other Developmental Activities 14.10.4. Pivotal Clinical Trials 14.10.5. Ongoing Current Pipeline Activity 14.11. Alunbrig (Brigatinib): Takeda Pharmaceuticals 14.11.1. Product Description 14.11.2. Regulatory Milestones 14.11.3. Pivotal Clinical Trials 14.11.4. Ongoing Current Pipeline Activity 14.11.5. Safety and Efficacy of Ongoing Clinical Trials 14.12. Alecensa (Alectinib): Hoffmann-La Roche 14.12.1. Product Description 14.12.2. Regulatory Milestones 14.12.3. Other Developmental Activities 14.12.4. Pivotal Clinical Trials 14.12.5. Ongoing Current Pipeline Activity
  13. 13. 14.13. Vitrakvi (Larotrectinib): Bayer Healthcare 14.13.1. Product Description 14.13.2. Regulatory Milestones 14.13.3. Other Developmental Activities 14.13.4. Pivotal Clinical Trials 14.13.5. Safety and Efficacy 14.14. Portrazza (Necitumumab): Eli Lilly 14.14.1. Product Description 14.14.2. Regulatory Milestones 14.14.3. Other Developmental Activities 14.14.4. Pivotal Clinical Trials 14.14.5. Ongoing Current Pipeline Activity 15. Emerging Therapies 15.1. Nazartinib (EGF816): Novartis Pharmaceuticals 15.1.1. Product Description 15.1.2. Clinical Development 15.1.3. Safety and Efficacy 15.2. Capmatinib (INC280): Novartis Pharmaceuticals 15.2.1. Product Description 15.2.2. Other Development Activities 15.2.3. Clinical Development 15.2.4. Safety and Efficacy
  14. 14. 15.3. Tepmetko (tepotinib): Merck KGaA 15.3.1. Product Description 15.3.2. Other Development Activities 15.3.3. Clinical Development 15.3.4. Safety and Efficacy 15.4. Merestinib: Eli Lilly and Company 15.4.1. Product Description 15.4.2. Clinical Development 15.4.3. Telisotuzumab Vedotin: AbbVie 15.4.4. Product Description 15.4.5. Clinical Development 15.4.6. Safety and Efficacy 15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development 15.5.1. Product Description 15.5.2. Other Development Activity 15.5.3. Clinical Development 15.5.4. Safety and Efficacy 15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development 15.6.1. Product Description 15.6.2. Clinical Development 15.6.3. Safety and Efficacy 15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
  15. 15. 15.7.1. Product Description 15.7.2. Clinical Development 15.7.3. Safety and Efficacy 15.8. X-396 (Ensartinib): Xcovery 15.8.1. Product Description 15.8.2. Clinical Development 15.8.3. Safety and Efficacy 15.9. Plinabulin: BeyondSpring Pharmaceuticals 15.9.1. Product Description 15.9.2. Clinical Development 15.9.3. Safety and Efficacy 15.10. Tedopi (OSE2101): OSE Immunotherapeutics 15.10.1. Product Description 15.10.2. Clinical Development 15.10.3. Safety and Efficacy 15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company 15.11.1. Product Description 15.11.2. Clinical Development 15.11.3. Safety and Efficacy 15.12. SAR408701: Sanofi 15.12.1. Product Description 15.12.2. Clinical Development
  16. 16. 15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer 15.13.1. Product Description 15.13.2. Clinical Development 15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics 15.14.1. Product Description 15.14.2. Clinical Development 15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation 15.15.1. Product Description 15.15.2. Clinical Development 15.15.3. Safety and Efficacy 15.16. TAK-788: Takeda 15.16.1. Product Description 15.16.2. Clinical Development 15.16.3. Safety and Efficacy 15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals 15.17.1. Product Description 15.17.2. Clinical Development 15.18. Avelumab (Bavencio): Merck KGaA and Pfizer 15.18.1. Product Description 15.18.2. Clinical Development 15.18.3. Safety and Efficacy 15.19. Veliparib (ABT-888): AbbVie
  17. 17. 15.19.1. Product Description 15.19.2. Clinical Development 15.19.3. Safety and Efficacy 15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene 15.20.1. Product Description 15.20.2. Other Developmental Activities 15.20.3. Clinical Development 15.20.4. Safety and Efficacy 15.21. Tesevatinib: Kadmon Corporation 15.21.1. Product Description 15.21.2. Clinical Development 15.21.3. Safety and Efficacy 15.22. Romiplostim: Amgen 15.22.1. Product Description 15.22.2. Clinical Development 15.23. Cabozantinib: Exelixis/Ipsen/Takeda 15.23.1. Product Description 15.23.2. Other Development Activities 15.23.3. Clinical Development 15.23.4. Safety and Efficacy 15.24. Sym015: Symphogen 15.24.1. Product Description
  18. 18. 15.24.2. Clinical Development 15.24.3. Safety and Efficacy 15.25. AMG 510: Amgen 15.25.1. Product Description 15.25.2. Clinical Development 15.25.3. Safety and Efficacy 15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited 15.26.1. Product Description 15.26.2. Clinical Development 15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals 15.27.1. Product Description 15.27.2. Clinical Development 15.27.3. Safety and Efficacy 15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc 15.28.1. Product Description 15.28.2. Clinical Development 15.28.3. Safety and Efficacy 15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA 15.29.1. Product Description 15.29.2. Clinical Development 15.29.3. Safety and Efficacy 16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
  19. 19. 16.1. Key Findings 16.2. Market Outlook: 7MM 17. PD-L1—Market Size 17.1. Total Market Size of PD-L1 NSCLC in the 7MM 17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM 17.3. United States Market Size 17.3.1. Total Market size of PD-L1 NSCLC in the United States 17.4. EU-5 Market Size 17.4.1. Germany Market Size 17.4.2. France Market Size 17.4.3. Italy Market Size 17.4.4. Spain Market Size 17.4.5. United Kingdom Market Size 17.5. Japan Market Size 17.5.1. Total Market size of PD-L1 NSCLC in Japan 18. BRAF Mutation—Market Size 18.1. Total Market Size of BRAF NSCLC in the 7MM 18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM 18.3. United States Market Size 18.3.1. Total Market size of BRAF NSCLC in the United States 18.4. EU-5 Market Size 18.4.1. Germany Market Size
  20. 20. 18.4.2. France Market Size 18.4.3. Italy Market Size 18.4.4. Spain Market Size 18.4.5. United Kingdom Market Size 18.5. Japan Market Size 18.5.1. Total Market size of BRAF NSCLC in Japan 19. c-MET Mutation—Market Size 19.1. Total Market Size of c-MET NSCLC in the 7MM 19.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM 19.3. United States Market Size 19.3.1. Total Market size of c-MET NSCLC in the United States 19.4. EU-5 Market Size 19.4.1. Germany Market Size 19.4.2. France Market Size 19.4.3. Italy Market Size 19.4.4. Spain Market Size 19.4.5. United Kingdom Market Size 19.5. Japan Market Size 19.5.1. Total Market size of c-MET NSCLC in Japan 20. EGFR Mutation—Market Size 20.1. Total Market Size of EGFR-positive NSCLC in the 7MM 20.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM
  21. 21. 20.3. United States Market Size 20.3.1. Total Market size of EGFR NSCLC in the United States 20.4. EU-5 Market Size 20.4.1. Germany Market Size 20.4.2. France Market Size 20.4.3. Italy Market Size 20.4.4. Spain Market Size 20.4.5. United Kingdom Market Size 20.5. Japan Market Size 20.5.1. Total Market size of NSCLC in Japan 21. ALK-Mutation—Market Size 21.1. Total Market Size of ALK NSCLC in the 7MM 21.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM 21.3. United States Market Size 21.3.1. Total Market size of ALK NSCLC in the United States 21.4. EU-5 Market Size 21.4.1. Germany Market Size 21.4.2. France Market Size 21.4.3. Italy Market Size 21.4.4. Spain Market Size 21.4.5. United Kingdom Market Size 21.5. Japan Market Size
  22. 22. 21.5.1. Total Market size of NSCLC in Japan 22. Market Access and Reimbursement of NSCLC Therapies 23. Market Drivers of NSCLC 24. Market Barriers of NSCLC 25. Appendix 25.1. Bibliography 25.2. Report Methodology 26. DelveInsight Capabilities 27. Disclaimer 28. About DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung- cancer-market Related Reports:  Non-Small Cell Lung Cancer Epidemiology Forecast to 2030  Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020  Non-Small Cell Lung Cancer Pipeline Insights, 2020 About DelveInsight DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

×